Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report for the non-interventional imposed PASS final report for the medicinal product(s) containing the active substances acitretin, alitretinoin or isotretinoin and concerned by the PASS final report, the scientific conclusions are as follows:

The risk-benefit balance of medicinal products containing the active substance acitretin, alitretinoin or isotretinoin concerned by the PASS final report remains unchanged but the PRAC recommends that the terms of the marketing authorisation(s) should be varied as follows:

- Update of the respective SmPC to remove the black triangle. The respective Package leaflet is updated accordingly.

A qualitative study is necessary to investigate barriers and reasons why certain measures part of the PPP are not always followed in clinical practice. The full protocol of the qualitative study should be submitted in a separate procedure, as soon as possible and no later than 6 months after the conclusion of the current procedure.

The MAHs should submit an updated RMP within 3 months after the finalisation of this PASS procedure.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for the results of the study for the medicinal product(s) containing the active substances acitretin, alitretinoin or isotretinoin and concerned by the PASS final report, the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) mentioned above is unchanged subject to the proposed changes to the product information. Furthermore, by finalising this study, the removal of the additional monitoring statement and the black triangle from the product information is warranted.

The CMDh reaches the position that the marketing authorisation(s) of the products concerned by this PASS final report should be varied.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Summary of Product Characteristics (new text **<u>underlined and in bold</u>,** deleted text ~~strike through~~)

▼ ~~This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section "Undesirable effects" for how to report adverse reactions~~

Amendments to be included in the relevant sections of the Package Leaflet (new text **<u>underlined and in bold</u>,** deleted text ~~strike through~~)

▼ ~~This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.~~

Annex III

Conditions to the Marketing Authorisation(s)

Changes to be made to the conditions of the marketing authorisations of medicinal products containing the active substances acitretin, alitretinoin, isotretinoin (oral formulations) concerned by the non-interventional imposed PASS final report.

The marketing authorisation holder(s) shall remove the following condition:

In order to assess the effectiveness of the updated risk minimisation measures in women of childbearing potential resulting from this referral procedure, MAH(s) of oral retinoids acitretin, alitretinoin and isotretinoin should conduct and submit the results of a drug utilisation study (DUS). The study design should aim to evaluate and quantify the effectiveness of the Risk Management Measures, and should include a pre- and post-implemented analysis and assessment. The clinical study report should be submitted to the relevant National Competent Authorities:	Within 48 months after Commission Decision

Annex IV

Timetable for the implementation of this position

Timetable for the implementation of the position

Adoption of CMDh position:	October 2023 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	26 November 2023
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	25 January 2024